Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Clinical trial NCT02937662 · COMPLETED

Trial details

NCT number: NCT02937662
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2016-10-01
Primary completion: 2020-04-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.